Arax Advisory Partners’s Sana Biotechnology SANA Stock Holding History

Arax Advisory Partners’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.7K	Sell	22,114 -36,914	-63%	-$145K	﹤0.01%	1584
2025 Q4	$240K	Sell	59,028 -105,903	-64%	-$474K	0.01%	951
2025 Q3	$586K	Buy	+164,931	New	+$596K	0.01%	846
2024 Q4	–	Sell	-150	Closed	-$624	–	2701
2024 Q3	$624	Hold	150	–	–	﹤0.01%	2370
2024 Q2	$819	Buy	+150	New	+$1.2K	﹤0.01%	2230

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Arax Advisory Partners's SANA Position: Q1 2026 in Review

Arax Advisory Partners reduced its Sana Biotechnology (SANA) stake by 63% in Q1 2026, selling an estimated $145K and leaving 22,114 shares worth $63.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

Arax Advisory Partners first reported a position in SANA in Q2 2024 and has held it in 5 quarters since. The position peaked at $586K in Q3 2025. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

Arax Advisory Partners held 22,114 shares of Sana Biotechnology worth $63.7K as of Q1 2026.
Arax Advisory Partners sold 36,914 Sana Biotechnology shares in Q1 2026, an estimated $145K.
Sana Biotechnology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1584 holding.
Arax Advisory Partners first reported a position in Sana Biotechnology in Q2 2024 and has held it in 5 quarters since.
Arax Advisory Partners's Sana Biotechnology position peaked at $586K in Q3 2025.
202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.